William Abramovits
About
In The Last Decade
William Abramovits
119 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 119
- Dermatology 1.5k
- Immunology and Allergy 692
- Epidemiology 369
- Immunology 310
- Physiology 234
Countries citing papers authored by William Abramovits
This map shows the geographic impact of William Abramovits's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Abramovits with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Abramovits more than expected).
Fields of papers citing papers by William Abramovits
This network shows the impact of papers produced by William Abramovits. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Abramovits. The network helps show where William Abramovits may publish in the future.
Co-authorship network of co-authors of William Abramovits
This figure shows the co-authorship network connecting the top 25 collaborators of William Abramovits. A scholar is included among the top collaborators of William Abramovits based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Abramovits. William Abramovits is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Libtayo® (Cemiplimab-rwlc) Injection for Intravenous Use. | 0 |
| 2 | SOTYKTUTM (Deucravacitinib 6-mg Tablets)- A New Agent for the Management of Adult Plaque Psoriasis. | 2 |
| 3 | ZORYVETM (Roflumilast) Cream: A Topical Phosphodiesterase-4 Inhibitor for the Treatment of Psoriasis. | 4 |
| 4 | 34 | |
| 5 | 29 | |
| 6 | 26 | |
| 7 | Zyclara (imiquimod) cream, 3.75%. | 15 |
| 8 | Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. | 19 |
| 9 | 79 | |
| 10 | 3 | |
| 11 | 11 | |
| 12 | 26 | |
| 13 | 9 | |
| 14 | 24 | |
| 15 | Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. | 19 |
| 16 | 4 | |
| 17 | 10 | |
| 18 | 9 | |
| 19 | 16 | |
| 20 | Third-party payer cost of atopic dermatitis and eczema in the United States | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.